Nevro downgraded to Sell from Neutral at Citi

Citi downgraded Nevro to Sell from Neutral with a price target of $9, down from $13.50. The spinal cord stimulator market recovery remains elusive and Nevro is facing painful diabetic neuropathy competition, the analyst tells investors in a research note. The firm says that “while the stock is not expensive by any means, it is unclear to us what gets it going.”